Piedmont Cancer Institute, Atlanta, Newnan, Fayette, Stockbridge logo for print
ATLANTA: 1800 Howell Mill Rd • Suite 800 • Atlanta, GA 30318 • 404-350-9853
FAYETTEVILLE: 1267 Highway 54 West • Suite 4200 • Fayetteville, GA 30214 • 678-829-1060
NEWNAN: 775 Poplar Rd. • Suite 310 • Newnan, GA 30265 • 770-251-2590
HENRY: 1240 Eagles Landing Parkway • Suite 260 • Stockbridge, GA 30281 • 678-854-9500
Menu

New Drug For Treating Advanced Breast Cancer


Eribulin (HALAVEN) was recently approved by the US Food and Drug Administration for women with advanced metastatic breast cancer. A large study showed that eribulin compared favorably to other chemotherapy drugs typically used after initial chemotherapy has failed and led to a longer survival. Dr. Charles Henderson who served as the Principal Investigator for PHOC for this study says “We were fortunate to participate in the registration trial of this new chemotherapy agent. Women with advanced metastatic breast cancer who have undergone at least 2 types of chemotherapy and their cancer continues to progress have few good options left.” Eribulin was found to lead to a longer survival by a few months when compared to the available chemotherapy options. He continues “It is an easy, quick infusion that takes 2-5 minutes and is done on a weekly basis, skipping every third week”. The side effects are manageable and typical for chemotherapy drugs. “Although we have made great progress in breast cancer over the past 15 years, thousands of women still die from the disease every year. The need for new, better therapies that help control cancer and extend the lives of our patients is more urgent than ever. I am proud that PCI has a history of having access to such breakthrough treatment options. Our patients benefit greatly.”



MDanderson cancer network certified member

Related Links